Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Genmab
Big Ten Cancer Research Consortium
Fondazione Italiana Linfomi - ETS
M.D. Anderson Cancer Center
Karyopharm Therapeutics Inc
Emory University
Columbia University
Artiva Biotherapeutics, Inc.
Cyteir Therapeutics, Inc.
Columbia University
M.D. Anderson Cancer Center
Duke University
Hoosier Cancer Research Network
Hoffmann-La Roche
Arbeitsgemeinschaft medikamentoese Tumortherapie
Ohio State University Comprehensive Cancer Center
Celgene
Aptevo Therapeutics
St. Petersburg State Pavlov Medical University
Hoffmann-La Roche
Weill Medical College of Cornell University
Sun Yat-sen University
St. Petersburg State Pavlov Medical University
Medical College of Wisconsin
Columbia University
St. Petersburg State Pavlov Medical University
Mayo Clinic
Weill Medical College of Cornell University
Swiss Cancer Institute
Seagen Inc.
University of Washington
Loyola University
Ohio State University Comprehensive Cancer Center
Lund University Hospital
Johannes Gutenberg University Mainz
University of Alabama at Birmingham
Teva Branded Pharmaceutical Products R&D, Inc.
GiovanniPascale
Kantonsspital Aarau
Jichi Medical University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Teva Branded Pharmaceutical Products R&D, Inc.
Southern Europe New Drug Organization
University of Leipzig